Medrad Interventional, a provider of cardio vascular products, is set to present its five year Thunder trial data.
The data will focus on target lesion revascularization comparing the Cotavance drug eluting balloon (DEB) catheter with Paccocath Technology to standard balloon angioplasty (POBA) in popliteal arteries of patients with peripheral arterial disease (PAD).
The Paccocath technology is a proprietary drug matrix which comprises paclitaxel and a radiologic contrast agent, Ultravist 370.
The techlogy is applied to the Cotavance balloon catheter and when it is inflated to dilate the narrowed vessel, paclitaxel is delivered directly to the diseased area.
Medrad Interventional senior vice president Jack Darby said they remain committed to further elucidate long-term clinical outcomes with the Cotavance paclitaxel eluting balloon catheter compared to or in combination with other interventional therapies through their large clinical studies and registry program.
Medrad is planning to file Cotavance Investigational Device Exemption (IDE) application for FDA approval.